hVIVO (LON:HVO) Announces Quarterly Earnings Results

hVIVO (LON:HVO) announced its quarterly earnings data on Tuesday. The company reported GBX (0.82) earnings per share (EPS) for the quarter, Digital Look Earnings reports. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%.

hVIVO Stock Down 5.2%

HVO opened at GBX 6.07 on Tuesday. hVIVO has a twelve month low of GBX 4.30 and a twelve month high of GBX 11. The company’s 50-day moving average price is GBX 6.83 and its two-hundred day moving average price is GBX 7.42. The stock has a market cap of £41.75 million, a price-to-earnings ratio of -6.97 and a beta of 1.69. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.